MBI Webinar on preclinical research into brain tumours and neurodegenerative disorders
Oncology, Neuroimmunology, Neuropharmacology and seminar by Dr Ekaterina (Caty) Salimova and Ms Sanjeevini Babu Reddiar
Hosted by Ad hoc
Thursday 06:30–07:40 Melbourne (GMT+10)
Ended
Abstract
WEBINAR 1 Breaking the barrier: Using focused ultrasound for the development of targeted therapies for brain tumours presented by Dr Ekaterina (Caty) Salimova, Monash Biomedical Imaging Glioblastoma multiforme (GBM) - brain cancer - is aggressive and difficult to treat as systemic therapies are hindered by the blood-brain barrier (BBB). Focused ultrasound (FUS) - a non-invasive technique that can induce targeted temporary disruption of the BBB – is a promising tool to improve GBM treatments. In this webinar, Dr Ekaterina Salimova will discuss the MRI-guided FUS modality at MBI and her research to develop novel targeted therapies for brain tumours. Dr Ekaterina (Caty) Salimova is a Research Fellow in the Preclinical Team at Monash Biomedical Imaging. Her research interests include imaging cardiovascular disease and MRI-guided focused ultrasound for investigating new therapeutic targets in neuro-oncology. - WEBINAR 2 Disposition of the Kv1.3 inhibitory peptide HsTX1[R14A], a novel attenuator of neuroinflammation presented by Sanjeevini Babu Reddiar, Monash Institute of Pharmaceutical Sciences The voltage-gated potassium channel (Kv1.3) in microglia regulates membrane potential and pro-inflammatory functions, and non-selective blockade of Kv1.3 has shown anti-inflammatory and disease improvement in animal models of Alzheimer’s and Parkinson’s diseases. Therefore, specific inhibitors of pro-inflammatory microglial processes with CNS bioavailability are urgently needed, as disease-modifying treatments for neurodegenerative disorders are lacking. In this webinar, PhD candidate Ms Sanju Reddiar will discuss the synthesis and biodistribution of a Kv1.3-inhibitory peptide using a [64Cu]Cu-DOTA labelled conjugate. Sanjeevini Babu Reddiar is a PhD student at the Monash Institute of Pharmaceutical Sciences. She is working on a project identifying the factors governing the brain disposition and blood-brain barrier permeability of a Kv1.3-blocking peptide.
Topics
Show 1 more topic
Related seminars
- Video · 1 h 29 min · Feb 23, 2023Veerle Visser-Vandewalle, MD, PhD & Marie Krüger, MD, University Hospital Cologne, Germany / Kantonsspital St. Gallen, Switzerland & UCL / Queensquare London, UK
Sparks, flames, and inferno: epileptogenesis in the glioblastoma microenvironment
Video · 59 min · Oct 7, 2020Jeff Noebels, Baylor College of MedicinePrecision Meets Ultrasound: Neuronavigation for tFUS with visor2
Nov 5, 2026Romain Duprat, ANT Neuro GmbH
Conferences in Oncology soon
All conferencesCancer Neuroscience: Neural Mechanisms as Therapeutic Targets in Cancer
Feb 21–24, 2027Keystone, United StatesHICCC Cancer Neuroscience Symposium
Oct 27, 2026New York, United States